Vera Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for TRUTAKNA (atacicept-vymj). This approval is for the indication of reducing proteinuria in adult patients diagnosed with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.